Patents by Inventor Oswald Quehenberger

Oswald Quehenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for identifying non-alcoholic fatty liver disease
    Patent number: 11105823
    Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 31, 2021
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, Oswald Quehenberger, Rohit Loomba
  • Differential diagnosis of liver disease
    Patent number: 11035846
    Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 15, 2021
    Assignee: The Regents of the University of California
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
    Publication number: 20200011848
    Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • Differential diagnosis of liver disease
    Patent number: 10422786
    Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: September 24, 2019
    Assignee: The Regents of the University of California
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • METHODS AND COMPOSITIONS FOR IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20180031585
    Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Inventors: Edward A. Dennis, Oswald Quehenberger, Rohit Loomba
  • DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
    Publication number: 20160305925
    Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis